204 related articles for article (PubMed ID: 20016053)
1. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
4. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Krishna R; Bergman AJ; Jin B; Garg A; Roadcap B; Chiou R; Dru J; Cote J; Laethem T; Wang RW; Didolkar V; Vets E; Gottesdiener K; Wagner JA
J Clin Pharmacol; 2009 Jan; 49(1):80-7. PubMed ID: 19004846
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans.
Dalvie D; Chen W; Zhang C; Vaz AD; Smolarek TA; Cox LM; Lin J; Obach RS
Drug Metab Dispos; 2008 Nov; 36(11):2185-98. PubMed ID: 18694908
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and Disposition of Siponimod, a Novel Selective S1P
Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
[TBL] [Abstract][Full Text] [Related]
8. Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
Lauring B; Liu Y; Li XS; Larson P; Moreau A; Farmer HF; Johnson-Levonas AO; Wagner JA; Lai E
J Clin Pharmacol; 2014 Jul; 54(7):765-75. PubMed ID: 24615657
[TBL] [Abstract][Full Text] [Related]
9. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
10. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
Krishna R; Gheyas F; Liu Y; Cote J; Laterza O; Ruckle JL; Wagner JA; Denker AE
J Clin Pharmacol; 2018 Feb; 58(2):254-262. PubMed ID: 28884824
[TBL] [Abstract][Full Text] [Related]
12. Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers.
Miao Z; Sun H; Liras J; Prakash C
Drug Metab Dispos; 2012 Mar; 40(3):568-78. PubMed ID: 22187487
[TBL] [Abstract][Full Text] [Related]
13. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
Teramoto T; Daida H; Ikewaki K; Arai H; Maeda Y; Nakagomi M; Shirakawa M; Watanabe Y; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Blaustein RO
Atherosclerosis; 2017 Jun; 261():69-77. PubMed ID: 28478132
[TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
15. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
16. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
Thomas T; Zhou H; Karmally W; Ramakrishnan R; Holleran S; Liu Y; Jumes P; Wagner JA; Hubbard B; Previs SF; Roddy T; Johnson-Levonas AO; Gutstein DE; Marcovina SM; Rader DJ; Ginsberg HN; Millar JS; Reyes-Soffer G
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1770-1775. PubMed ID: 28729361
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
[TBL] [Abstract][Full Text] [Related]
18. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.
Kassahun K; McIntosh I; Koeplinger K; Sun L; Talaty JE; Miller DL; Dixon R; Zajic S; Stoch SA
Drug Metab Dispos; 2014 May; 42(5):818-27. PubMed ID: 24553380
[TBL] [Abstract][Full Text] [Related]
19. Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
Garg A; Maes A; Corr C; Jin B; Wadhwa T; Handa N; Van Dyck K; De Lepeleire I; Shah J; Wagner JA; Krishna R
J Clin Pharmacol; 2011 Mar; 51(3):436-9. PubMed ID: 20418508
[No Abstract] [Full Text] [Related]
20. Anacetrapib: hope for CETP inhibitors?
Gurfinkel R; Joy TR
Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
